Consistent with long-term outcomes of ZUMA-1 study as well as commercial anti-CD19 CAR T cell therapy4,48–50, three months or six months post CAR T-cell infusion were both feasible and efficient timepoints for predicting long-term outcome of CAR-T cell therapy in aggressive B-cell lymphomas. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.